Ozempic vs Wegovy: What's the Difference?

If you've heard about Ozempic and Wegovy and wondered what separates them, you're not alone. These two medications dominate conversations about metabolic health, weight loss, and diabetes management — yet they're frequently confused with each other. The confusion is understandable: they share an active ingredient, they're made by the same company (Novo Nordisk), and they look nearly identical in the pharmacy.

But the differences matter significantly for prescribing, insurance coverage, dosing, and clinical outcomes. This guide breaks down everything you need to know — clearly, accurately, and without the marketing hype.

Same drug, different doses

At the molecular level, Ozempic and Wegovy are chemically identical. Both contain semaglutide — a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a naturally occurring hormone involved in blood sugar regulation and appetite signalling.

Semaglutide works by:

• Stimulating insulin release in response to blood glucose, helping manage blood sugar in type 2 diabetes.
• Suppressing glucagon (a hormone that raises blood sugar), reducing hepatic glucose production.
• Slowing gastric emptying, making food move more slowly from the stomach, increasing feelings of fullness.
• Acting on brain appetite centres, reducing hunger and calorie intake.

FDA approvals: what each is prescribed for

This is the most important distinction. The FDA approval defines the intended medical use, influences insurance coverage, and determines who is a clinically appropriate candidate.

Ozempic's approval

Ozempic received FDA approval in December 2017 for two primary indications:

1. Glycaemic control in type 2 diabetes: As an adjunct to diet and exercise to improve blood sugar (A1C) levels in adults with type 2 diabetes mellitus.
2. Cardiovascular risk reduction: To reduce the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease.

Weight loss is a well-documented side effect of Ozempic, but it is not its primary approved indication. Doctors who prescribe Ozempic for weight loss in non-diabetic patients are doing so off-label.

Wegovy's approval

Wegovy was approved by the FDA in June 2021 specifically for chronic weight management. Eligible patients are adults with:

• A BMI of 30 or greater (obesity), OR
• A BMI of 27 or greater (overweight) plus at least one weight-related condition such as hypertension, type 2 diabetes, or high cholesterol.

In 2024, the FDA also expanded Wegovy's approval to include cardiovascular risk reduction in obese or overweight adults with existing cardiovascular disease — matching Ozempic's secondary indication but for a weight-management patient population.

Dosing schedules compared

Both Ozempic and Wegovy use the same titration approach: start low, increase every 4 weeks to allow your body to adjust and minimise side effects. Both are administered as once-weekly subcutaneous injections (under the skin), typically in the stomach, thigh, or upper arm.

Wegovy's extended titration schedule — reaching maintenance over 16+ weeks — is intentional. The higher final dose (2.4mg) drives greater weight loss outcomes, but requires careful dose escalation to manage GI side effects. The STEP clinical trial programme that supported Wegovy's approval used this specific titration.

Side effects: are they the same?

Because both medications contain semaglutide, the side effect profile is qualitatively identical. The severity and frequency may differ somewhat due to the higher doses in Wegovy's maintenance phase.

GI side effects typically peak during dose escalation and diminish as your body adapts. Tracking side effects precisely — noting their timing, severity, and duration — helps you and your doctor make better dosing decisions. Our guide to tracking Ozempic side effects walks through the best logging approach.

Cost and insurance coverage

Cost is one of the most practically significant differences between Ozempic and Wegovy, primarily because of insurance coverage differences.

• Ozempic list price: Approximately $900–$1,000/month without insurance. Most commercial insurance plans cover Ozempic for patients with type 2 diabetes, making out-of-pocket costs significantly lower.
• Wegovy list price: Approximately $1,300–$1,700/month without insurance. Insurance coverage for weight management medications varies widely. Many commercial plans cover it; Medicare Part D coverage expanded after cardiovascular indication approval.
• Savings cards: Novo Nordisk offers savings programmes for both medications. Eligible commercially insured patients may pay as little as $25/month through the manufacturer's savings card.
• Generic semaglutide: No FDA-approved generic is currently available. Compounded semaglutide products exist but exist in a regulatory grey area — quality and safety are not FDA-verified.

Which one is right for me?

The answer depends on your medical situation, not personal preference:

• If you have type 2 diabetes: Ozempic is the appropriate first-line semaglutide option. It manages blood sugar and may provide cardiovascular protection.
• If you have obesity or overweight with a comorbidity and your primary goal is weight loss: Wegovy is the specifically approved and studied formulation. Its higher maintenance dose (2.4mg vs 2mg max for Ozempic) is associated with greater average weight loss — approximately 15% body weight in the STEP trials vs approximately 9–12% in Ozempic studies.
• If you have both diabetes and want weight loss: Your doctor may consider Ozempic first; some patients are transitioned to Wegovy if weight management becomes the primary goal.

This is ultimately a clinical decision. Variables including your A1C, BMI, cardiovascular history, other medications, and insurance coverage all factor into the right choice for you.

Tracking your GLP-1 response with tr8ck

Whether you're on Ozempic or Wegovy, the quality of information you bring to your doctor's appointments directly affects the quality of care you receive. Generic reports like "I felt nauseous sometimes" are far less useful than data showing exactly which days side effects occurred, their severity, and how they correlate with your injection timing, food choices, and activity.

tr8ck's GLP-1 tracking system is built for this. Each week, you log:

• Injection date and dose
• Side effects by type and severity (1–10 scale)
• Weight
• Appetite changes
• Energy and mood scores
• Sleep quality
• Any medications taken alongside (see our medication tracker)

Over weeks and months, tr8ck surfaces patterns specific to your response — which foods worsen nausea, whether side effects cluster in the first 48 hours post-injection, how your weight trend compares to expected clinical trajectories. This is the kind of personalised insight that makes GLP-1 therapy more effective and more manageable.

FAQ